Shots: Regeneron has entered a strategic research collaboration with Parabilis to discover & develop multiple therapeutics using Parabilis’ Helicon peptide platform, with a focus on Antibody-Helicon Conjugates (AHCs) Regeneron will lead development, manufacturing, & global commercialization, while Parabilis will receive $125M, incl. $50M upfront & a $75M commitment toward its next equity financing, subject to…